search
Back to results

Modal Day Analysis of Self Monitoring Blood Glucose Versus Continuous Glucose Monitoring

Primary Purpose

Type 2 Diabetes

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
SMBG to guide clinical decisions
SMBG and CGM
Sponsored by
HealthPartners Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes focused on measuring Type 2 Diabetes, A1c, Continuous Glucose Monitoring, Blood Glucose

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or female subjects ≥18 and ≤75 years of age
  • Clinical diagnosis of diabetes
  • Diabetes duration ≥ 1 year
  • HbA1c ≥7.2%
  • Diabetes can be treated with any therapy including medical nutrition therapy alone and any pharmaceutical therapy

Exclusion Criteria:

  • Taken prednisone or cortisone medications in the previous 30 days
  • Currently pregnant or planning pregnancy during the study period
  • Presence of any severe medical or psychological condition or chronic conditions/infections that in the opinion of the Investigator would compromise the subject's safety or successful participation in the study
  • Unable to follow the study protocol
  • Unable to speak, read and write in English

Sites / Locations

  • International Diabetes Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

SMBG Only

SMBG and CGM

Arm Description

You will measure your blood glucose 4 times daily by finger sticks using a blood glucose meter and you will also wear a CGM device. The CGM measurements will be blinded (neither you nor the study doctor will be able to see the CGM measurements until your final study visit). Only your SMBG measurements will be considered to help manage your diabetes. Your medications will be changed or adjusted based on your HbA1c and/or glucose readings with a goal to achieve an HbA1c level of less than 7%.

You will measure your blood glucose 4 times daily by finger sticks using a blood glucose meter and you will also wear a CGM device. The CGM measurements will be downloaded at each study visit and will be considered along with your SMBG measurements to help manage your diabetes. Your medications will be changed or adjusted based on your HbA1c and/or glucose readings with a goal to achieve an HbA1c level of 7%.

Outcomes

Primary Outcome Measures

Evaluate the efficacy of SMBG for clinical decisions related to the management of type 2 diabetes.

Secondary Outcome Measures

Determine the incremental benefit of CGM for clinical decision-making.

Full Information

First Posted
February 18, 2010
Last Updated
November 25, 2015
Sponsor
HealthPartners Institute
Collaborators
International Diabetes Center at Park Nicollet, Abbott Diabetes Care
search

1. Study Identification

Unique Protocol Identification Number
NCT01072565
Brief Title
Modal Day Analysis of Self Monitoring Blood Glucose Versus Continuous Glucose Monitoring
Official Title
Optimization of SMBG Employing Modal Day Analysis: Examining Clinical Decision-making Processes Using Blinded FreeStyle Navigator Continuous Glucose Monitoring System (CGM)
Study Type
Interventional

2. Study Status

Record Verification Date
April 2013
Overall Recruitment Status
Completed
Study Start Date
February 2010 (undefined)
Primary Completion Date
January 2012 (Actual)
Study Completion Date
January 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
HealthPartners Institute
Collaborators
International Diabetes Center at Park Nicollet, Abbott Diabetes Care

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the effectiveness of Self Monitoring of Blood Glucose (SMBG) for clinical decisions related to the management of type 2 diabetes and to determine the benefit of using Continuous Glucose Monitoring (CGM) for clinical diabetes management.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
Keywords
Type 2 Diabetes, A1c, Continuous Glucose Monitoring, Blood Glucose

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Factorial Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
91 (Actual)

8. Arms, Groups, and Interventions

Arm Title
SMBG Only
Arm Type
Active Comparator
Arm Description
You will measure your blood glucose 4 times daily by finger sticks using a blood glucose meter and you will also wear a CGM device. The CGM measurements will be blinded (neither you nor the study doctor will be able to see the CGM measurements until your final study visit). Only your SMBG measurements will be considered to help manage your diabetes. Your medications will be changed or adjusted based on your HbA1c and/or glucose readings with a goal to achieve an HbA1c level of less than 7%.
Arm Title
SMBG and CGM
Arm Type
Active Comparator
Arm Description
You will measure your blood glucose 4 times daily by finger sticks using a blood glucose meter and you will also wear a CGM device. The CGM measurements will be downloaded at each study visit and will be considered along with your SMBG measurements to help manage your diabetes. Your medications will be changed or adjusted based on your HbA1c and/or glucose readings with a goal to achieve an HbA1c level of 7%.
Intervention Type
Other
Intervention Name(s)
SMBG to guide clinical decisions
Intervention Description
The investigator will base clinical decisions on A1c and modal day analysis of SMBG.
Intervention Type
Other
Intervention Name(s)
SMBG and CGM
Intervention Description
The investigator will base clinical decisions on A1c, modal day analysis of SMBG and CGM data.
Primary Outcome Measure Information:
Title
Evaluate the efficacy of SMBG for clinical decisions related to the management of type 2 diabetes.
Time Frame
Three, six and nine months.
Secondary Outcome Measure Information:
Title
Determine the incremental benefit of CGM for clinical decision-making.
Time Frame
Three, six and nine months.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female subjects ≥18 and ≤75 years of age Clinical diagnosis of diabetes Diabetes duration ≥ 1 year HbA1c ≥7.2% Diabetes can be treated with any therapy including medical nutrition therapy alone and any pharmaceutical therapy Exclusion Criteria: Taken prednisone or cortisone medications in the previous 30 days Currently pregnant or planning pregnancy during the study period Presence of any severe medical or psychological condition or chronic conditions/infections that in the opinion of the Investigator would compromise the subject's safety or successful participation in the study Unable to follow the study protocol Unable to speak, read and write in English
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Roger S Mazze, PhD
Organizational Affiliation
International Diabetes Center at Park Nicollet
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Elinor S Strock, APRN, BC
Organizational Affiliation
International Diabetes Center at Park Nicollet
Official's Role
Principal Investigator
Facility Information:
Facility Name
International Diabetes Center
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55416
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Modal Day Analysis of Self Monitoring Blood Glucose Versus Continuous Glucose Monitoring

We'll reach out to this number within 24 hrs